Current treatments for African trypanosomiasis are either toxic, costly, difficult to administer, or prone to elicit resistance. This study evaluated the activity of bisnaphthalimidopropyl (BNIP) derivatives against Trypanosoma brucei. BNIPDiaminobutane (BNIPDabut), the most active of these compounds, showed in vitro inhibition in the single-unit nanomolar range, similar to the activity in the reference drug pentamidine, and presented low toxicity and adequate metabolic stability. Additionally, using a murine model of acute infection and live imaging, a significant decrease in parasite load in BNIPDabut-treated mice was observed. However, cure was not achieved. BNIPDabut constitutes a new scaffold for antitrypanosomal drugs that deserves further consideration.
TEXT
African trypanosomiasis is an infectious disease caused by parasites of the species Trypanosoma brucei. The parasite is transmitted by an insect vector, the tsetse fly (Glossina spp.). The disease is distributed mainly on the African continent, with distinct subspecies causing different forms of human disease. T. brucei gambiense produces a chronic form of infection that may last for years and was responsible for nearly 98% of trypanosomiasis cases in the past decade. The acute form is caused by T. brucei rhodesiense and usually kills the host within weeks, accounting for the remaining 2% of reported cases (1, 2) .
Since vaccination remains elusive and vector control strategies are frequently insufficient, chemotherapy is still the most efficient option for controlling the disease (2) (3) (4) (5) . However, the drugs in current use have many drawbacks, mostly related to cost, effectiveness, toxicity, difficulty of administration, and appearance of resistance (6) . Therefore, the development of new drugs is urgently needed.
Bisnaphthalimidopropyl (BNIP) derivatives have been shown to possess anticancer activity (7) (8) (9) (10) (11) and to have activity against a related trypanosomatid, Leishmania infantum (12) (13) (14) . The potential activity of three BNIP derivatives previously synthetized (>96% pure [10, 11, 15] ), namely, BNIPDiaminobutane (BNIPDabut), BNIPDiaminoheptane (BNIPDahep), and BNIPDiaminooctane (BNIPDaoct) (Fig. 1A) , against T. brucei brucei Lister 427 bloodstream forms (BSFs), was investigated. These derivatives were selected from a series of compounds on the basis of preliminary studies of bioavailability and in vitro and in vivo activity against T. brucei and L. infantum (12; our unpublished data). The in vitro antiparasitic activity was assessed using a resazurin assay, as previously described, with minor modifications (incubation with 10 3 parasites/well, in 200 μl [16] ). All three BNIPs demonstrated a potent inhibitory effect on parasite growth, with a 50% inhibitory concentration (IC50) within the nanomolar range ( Fig. 1B ; Table 1 ). BNIPDabut was the most active compound, with a mean IC50 (± standard deviation [SD]) of 2.4 ± 1.0 nM, similar to that of the reference drug pentamidine (mean IC50 [± SD], 2.9 ± 0.7 nM; Table 1 ). Since this class of compounds has been described as a group of inhibitors of the L. infantum Silent information regulator 2-related protein 1 (LiSir2rp1; GenBank accession number AAN39039.1) (15), we evaluated whether inhibition of the T. brucei orthologue TbSir2rp1 (GenBank accession number AAX70528.1) is a possible mechanism of action. Whereas BNIPDabut was shown to inhibit the NAD + -dependent deacetylase activity of TbSir2rp1 with an IC50 (± SD) of 155 ± 42 μM, suggesting that this is not the major mechanism of action (data not shown), LiSir2rp1 was inhibited with an IC50 (± SD) of 35.0 ± 5.8 μM (15) . The 47% identity between LiSir2rp1 and TbSir2rp1 obtained by protein sequence alignment (Clone Manager 9, BLOSUM 62 scoring matrix) Version: Postprint (identical content as published paper) This is a self-archived document from i3S -Instituto de Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our publications, please visit http://repositorio-aberto.up.pt/ A01/00 might explain the differences observed (17). Moreover, no correlation between the enzymatic inhibition and activity toward T. brucei parasites was observed. To evaluate in vitro toxicity toward mammalian cells, all the compounds were studied with the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay (18) in THP-1-derived macrophages and two primary cell cultures, rat cortical neurons and mouse hepatocytes ( Table 2 ). The 50% cytotoxic concentration (CC50) values for these molecules translate into selectivity indexes (SIs) higher than 100 (SI = CC50/IC50). All the BNIP derivatives exhibited a high SI, with BNIPDabut in particular being at least 800 times more selective toward T. brucei parasites. All the BNIPs had potency and selectivity that warranted additional characterization ( Table 2) . The sum of these values was ranked posteriorly to create combined injury criteria that varied from no injury (0) to low injury (1 to <5), moderate injury (≥5 to <12), and high injury (≥12). All BNIPs showed a dose-dependent injury score close to that of pentamidine in both cell types ( Fig. 2A and B ). BNIPDabut had a toxicity profile indistinguishable from that of the reference drug pentamidine.
To infer metabolic stability, mouse microsomes were incubated over 45 min with each compound at 5 μM, and each drug was quantified by liquid chromatography-tandem mass spectrometry. Similarly to pentamidine, BNIPDabut was more stable than BNIPDahep and BNIPDaoct; 95% to 100% of the drug was not metabolized (Table 3 ). This high metabolic stability is an indicator that the molecule is not easily subjected to common inactivation or loss of potency by reactions catalyzed by liver enzymes and is kept intact in circulation for longer periods.
To determine the pharmacokinetics of BNIPDabut, a 10-mg/kg dose was administered to BALB/c mice by intravenous injection. Five minutes later, a concentration of 58 nM was achieved and, during the following 24 h, remained higher than 41 nM (data not shown); thus, the concentration was approximately eight times higher than the calculated IC90.
Taking into consideration the previous results, we chose BNIPDabut for in vivo efficacy studies. All the experiments involving animals were carried out in accordance with the Institute for Molecular and Cell Biology Animal Ethics Committees and the Portuguese and European Authorities for Animal Health guidelines. T. brucei brucei Lister 427 parasites were transfected with a construct kindly provided by M. Taylor, in which the red-shifted luciferase gene (PpyRE9h) is flanked by 5′VSG/3′tubulin (22). After transfection, clones were screened for bioluminescent signal, and the ones that expressed the highest levels were selected. Their in vitro growth was compared with that of wild-type parasites and was found to be similar (data not shown). In vitro detection limits were also analyzed for BSFs in a 96-well plate and determined to be approximately 2,500 cells (data not shown). Female BALB/c mice were (Fig. 3A) . No adverse effects were observable following any administration regimen. Treatment efficacy was followed through whole-animal live imaging using an IVIS Lumina LT (PerkinElmer). Parasitemia was also assessed, and animals were euthanized after reaching a parasite concentration of 10 8 parasites/ml. Similarly to pentamidine, two administrations of either 10 or 20 mg/kg BNIPDabut efficiently reduced parasitemia below the detection limit (5 × 10 4 /ml) (Fig. 3B) . However, whole-mouse imaging revealed that a reduction of bioluminescent signal to the background level (obtained with noninfected mice) was achieved only in mice treated with 20 mg/kg of BNIPDabut during at least 5 consecutive days, as opposed to 2 days of treatment for the pentamidine group. Although treatment with 20 mg/kg BNIPDabut apparently cleared the infection, cure was not achieved; the parasite burden relapsed when treatment was stopped (Fig. 3B) . Indeed, BNIPDabut (10 and 20 mg/kg) treatment increased survival of the mice, but in contrast to those that received pentamidine, these animals were not cured (Fig. 3C) . A hypothesis is that BNIPDabut, although highly trypanocidal, cannot reach and clear all parasites due to potency, distribution, or both. A frequent observation was that the recurrence of parasitemia was preceded by imaging of parasite loads in the peritoneal zone, where animals were originally injected with the parasites. It has been demonstrated that trypanosomes invade extravascular tissues as a defense mechanism against host immunity and that this process may be related to relapses after treatment interruption (23, 24). Indeed, the presence of parasites in the extravascular tissues might explain the discrepancy of radiance values between days 4 and 12, while average parasitemia levels remained similar in mice treated with BNIPDabut (10 or 20 mg/kg) (Fig. 3C) . Nonetheless, it remains to be elucidated whether BNIPDabut is active in a mouse model of late-stage disease, as this is the central objective in drug discovery against human African trypanosomiasis. Additional chemical modifications to BNIPDabut may improve potency and/or distribution of the drug while maintaining or improving the toxicity and metabolism profiles.
In conclusion, this work demonstrates that BNIPDabut has potent in vitro and in vivo antitrypanosomal activity with acceptable toxicity and high metabolic stability. However, chemical modifications are needed to improve its pharmacodynamic and/or pharmacokinetic properties.
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